FIELD: medicine, oncology.
SUBSTANCE: invention proposes using a medicine valsartan as an antagonist of AT-1 receptors and a modulator of AT-2 receptors in treatment of lung or mammary glands invasive cancer. All carcinomas comprise AT-2 receptors while in hyperplasia of normal epithelial cells AT-2 receptors are localized only. This allows carrying out both diagnosis of malignant tumor development and treatment indicated diseases with valsartan owing to modulation of AT-2 receptors, i. e. based on change of the host biological response for tumor cells.
EFFECT: improved and valuable medicinal properties of medicine agent.
13 tbl, 12 ex
Authors
Dates
2006-03-20—Published
1999-12-22—Filed